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impairs CCR5 binding affinity while increasing 
replicative capacity
Javier Garcia‑Perez3, Isabelle Staropoli1,2, Stéphane Azoulay4, Jean‑Thomas Heinrich4, Almudena Cascajero3, 
Philippe Colin1,2,5, Hugues Lortat‑Jacob6,7,8, Fernando Arenzana‑Seisdedos1,2, Jose Alcami3, 
Esther Kellenberger4 and Bernard Lagane1,2*
Abstract 
Background: Maraviroc (MVC) is an allosteric CCR5 inhibitor used against HIV‑1 infection. While MVC‑resistant viruses 
have been identified in patients, it still remains incompletely known how they adjust their CD4 and CCR5 binding 
properties to resist MVC inhibition while preserving their replicative capacity. It is thought that they maintain high 
efficiency of receptor binding. To date however, information about the binding affinities to receptors for inhibitor‑
resistant HIV‑1 remains limited.
Results: Here, we show by means of viral envelope (gp120) binding experiments and virus‑cell fusion kinetics that a 
MVC‑resistant virus (MVC‑Res) that had emerged as a dominant viral quasispecies in a patient displays reduced affini‑
ties for CD4 and CCR5 either free or bound to MVC, as compared to its MVC‑sensitive counterpart isolated before MVC 
therapy. An alanine insertion within the GPG motif (G310_P311insA) of the MVC‑resistant gp120 V3 loop is responsi‑
ble for the decreased CCR5 binding affinity, while impaired binding to CD4 is due to sequence changes outside V3. 
Molecular dynamics simulations of gp120 binding to CCR5 further emphasize that the Ala insertion alters the struc‑
ture of the V3 tip and weakens interaction with CCR5 ECL2. Paradoxically, infection experiments on cells expressing 
high levels of CCR5 also showed that Ala allows MVC‑Res to use CCR5 efficiently, thereby improving viral fusion and 
replication efficiencies. Actually, although we found that the V3 loop of MVC‑Res is required for high levels of MVC 
resistance, other regions outside V3 are sufficient to confer a moderate level of resistance. These sequence changes 
outside V3, however, come with a replication cost, which is compensated for by the Ala insertion in V3.
Conclusion: These results indicate that changes in the V3 loop of MVC‑resistant viruses can augment the efficiency 
of CCR5‑dependent steps of viral entry other than gp120 binding, thereby compensating for their decreased affinity 
for entry receptors and improving their fusion and replication efficiencies. This study thus sheds light on unsuspected 
mechanisms whereby MVC‑resistant HIV‑1 could emerge and grow in treated patients.
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Background
The entry of human immunodeficiency virus type 1 
(HIV-1) into host cells starts with the binding of the 
surface subunit (gp120) of the viral envelope glycoprotein 
(Env) to cell surface CD4. This triggers conformational 
rearrangements in gp120 that allow it to interact with a 
coreceptor, either CC chemokine receptor 5 (CCR5) or 
the CXC chemokine receptor 4 (CXCR4) that are G-pro-
tein coupled receptors [1]. Elements in gp120 critical for 
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coreceptor binding comprises the third variable loop V3 
and a four-stranded bridging sheet shaped from the V1/
V2 stem and the C4 region [2–4]. The bridging sheet and 
the base of V3 are thought to interact with the N-termi-
nus domain of the coreceptor, while the tip of V3 inter-
acts with its second extracellular loop (ECL2) [5–8]. 
Interaction of gp120 with the coreceptor then leads to 
exposure of the transmembrane subunit (gp41) of Env, 
which inserts into the host cell plasma membrane and 
entails the viral fusion process [6, 9, 10]. Two entry inhib-
itors are currently used for treatment of HIV infection, 
i.e. the fusion inhibitor enfuvirtide (T20) and the CCR5 
ligand maraviroc (MVC) (for review see Ref. [11]).
MVC belongs to a class of small molecule CCR5 inhibi-
tors acting via an allosteric mechanism [12]. The com-
pound binds to a CCR5 transmembrane cavity distinct 
from the binding sites for chemokines and gp120 and 
changes the coreceptor conformation in such a way that 
HIV/CCR5 interactions are impaired [13–15]. Resist-
ance to MVC has been reported both in vitro and in vivo 
and results from viruses that have acquired the ability 
to use MVC-bound CCR5 in addition to free CCR5 for 
entry into cells [16–19]. This is manifested by maximal 
percents of infection inhibition (MPI) that are less than 
100% at a saturating inhibitor concentration, with MPI 
values that decrease with increased abilities of resistant 
viruses to use the inhibitor-bound receptor relative to 
free CCR5 [19, 20]. Resistance to allosteric inhibitors has 
mapped to sequence changes in the V3 loop, making the 
virus to interact with CCR5 regions whose conformation 
is spared by the inhibitor (e.g. the N-terminus) [17–19, 
21–24]. Resistance could also occur with no V3 changes 
and involve mutations in gp41 or the CD4-binding site 
of gp120 [25–28], suggesting that alterations of either 
of the different steps in HIV entry may compensate for 
impaired interactions with inhibitor-bound CCR5.
Acquisition of resistance to allosteric inhibitors can 
result in viruses that have a reduced replicative capacity, 
thereby leading to resistance mutations that revert rap-
idly when treatment with the inhibitor is discontinued 
[24, 29, 30]. In contrast, other resistant viruses showed 
no fitness loss [31]. In some cases, inhibitors can select 
for resistant viruses showing a reduced infectivity in 
some particular cells such as macrophages or central 
memory CD4+ T cells (TCM cells), suggesting that con-
tinued treatment with those inhibitors might be benefi-
cial for some patients even in the context of virological 
failure [16, 32]. This, unfortunately, is not always the case 
as improved infectivity of a MVC-resistant HIV-1 has 
recently been described in TCM cells in the presence of 
the inhibitor [33].
Resistance to CCR5 inhibitors and replicative capacity 
are thought to be closely related to the ability of viruses 
to bind to entry receptors, in particular to CCR5 in its 
inhibitor-bound conformation. To date however, infor-
mation about the binding affinities to CD4 and CCR5 for 
inhibitor-resistant HIV-1 remains scarce. Recently, the 
development of the 293-Affinofile receptor affinity pro-
filing system has provided important clues on the rela-
tive efficiencies of CD4 and CCR5 usages for viral entry 
(for review see Ref. [34]). In particular, high efficiency 
of CCR5 usage (i.e. low CCR5 dependence) has in many 
cases been correlated to high level of resistance to CCR5 
inhibitors, making it a possibility that the level of resist-
ance is related to the virus ability to bind to inhibitor-
bound CCR5 [17, 32]. However, given that CCR5 may 
contribute to different steps of HIV entry (e.g. interac-
tions with CD4, formation of the fusion pore, trigger-
ing of signaling pathways), the extent to which a virus is 
dependent on CCR5 could have nothing to do with CCR5 
binding affinity. The same seems also to be true for rep-
licative capacity. Indeed, previous works showed that 
the extent to which fusion and replication are inhibited 
by CCR5 ligands may not be correlated to inhibition effi-
ciency of Env/CCR5 interactions [8, 14, 35].
Here, we combined binding assays with purified gp120, 
virus infections in target cells with varying receptor 
expression levels, virus-cell fusion assays and molecular 
dynamics simulations to investigate the CD4 and CCR5 
binding properties of a MVC-sensitive and a MVC-resist-
ant Envs. Results revealed that the MVC-resistant Env 
has a severely impaired ability to engage both receptors 
in the absence and in the presence of MVC, as compared 
to the MVC-sensitive Env. In particular, the V3 loop of 
the MVC-resistant Env contains an uncommon insertion 
of an Alanine within the highly conserved GPGR motif 
(G310_P311insA), which we identified to be responsible 
for the decreased CCR5 binding affinity while, none-
theless, allowing the virus to use CCR5 efficiently and 
thereby increasing its fusion and replication efficien-
cies. This study thus highlights unsuspected mechanisms 
whereby HIV could develop resistance to CCR5 allosteric 
inhibitors and evolve as a dominant viral quasispecies in 
patients.
Results
The MVC-sensitive and MVC-resistant isolates we used 
here (hereafter referred to as MVC-Sens and MVC-Res) 
represent the dominant circulating viruses isolated from 
a patient of the MOTIVATE clinical trial before and 
after MVC therapy, respectively (Pfizer INC, NY, per-
sonal communication). Analysis of the MVC-Res Env 
sequence shows 32 mutations as compared to MVC-Sens 
Env, as well as eight amino acid insertions (Figure 1). Our 
Env sequences are similar to those reported in two pre-
vious papers [17, 33], except in the N- and C-terminal 
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Figure 1 Cloning, sequence analysis and site‑directed mutants of MVC‑Sens and MVC‑Res Envs. a Schematic representation of the proviral vector 
pNL‑KspI/env/NotI‑Ren. The KspI site was introduced in the proviral clone pNL4‑3Ren to allow the cloning of MVC‑Sens and MVC‑Res gp160. Analysis 
of the MVC‑Res Env sequence shows 32 mutations as compared to MVC‑Sens Env, 18 within gp120 and 14 within gp41, as well as eight amino acid 
insertions within gp120. The V3 loop of MVC‑Res Env contains two changes, the P308S mutation and an insertion of an Alanine within the GPGR tip 
(G310_P311insA). The MVC‑Sens and MVC‑Res Env sequences are similar to those reported in two previous papers, except in the N‑ and C‑terminal 
parts where we noted several amino acid changes. Indeed, in the sequences used in the references [17] and [33], which are deposited in the Los 
Alamos HIV Sequence Database, the 41 first residues and the 105 last residues originate from the HxB2 HIV‑1 strain. b Amino acid sequences of the 
V3 loops of the different site‑directed mutants of MVC‑Sens and MVC‑Res used in this study. S and R refer to the parental sequences from which 
the mutant sequences are derived. Dots indicate residues that are identical to those of the parental Env sequence, and dashes indicate gaps. The 
sequence of the V3 loop of gp120 from the HIV‑1 strain Bx08, to which MVC‑Sens and MVC‑Res Envs are compared in this study, is also shown. The 
first Cys residue of the V3 loop is equivalent to C296 in the HXB2 sequence and thus noted as such in the MVC‑Sens, MVC‑Res and Bx08 V3 sequences.
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regions where we noted several amino acid changes 
(see the legend of Figure  1 for more details). The V3 
loop of MVC-Res Env contains two changes, the P308S 
mutation and the Ala insertion within the GPGR motif 
(G310_P311insA), which were described to be necessary 
for MVC resistance in NP2-CD4/CCR5 cells [17, 33]. 
However, whether other regions of the resistant Env play 
a role as well as the individual contributions of the two 
changes within the V3 loop in the phenotypic properties 
of MVC-Res have not been investigated.
Genetic‑phenotypic relationships of the MVC sensitive 
and MVC resistant Envs
As the first step to study the mechanisms of MVC resist-
ance, we cloned the sequences encoding MVC-Sens and 
MVC-Res Envs into the proviral vector pNL-KspI/env/
NotI-Ren derived from the pNL4-3Ren viral clone [36] to 
produce replication-competent viruses (Figure  1). Then, 
we first performed MVC resistance assays in U87-CD4/
CCR5 cells, which are typically used in the PhenoSense™ 
Entry assay for assessment of HIV-1 resistance to CCR5 
entry inhibitors [19]. At 30 h post infection in the pres-
ence or absence of increasing MVC concentrations, cell 
lysates were examined for their luciferase activity as read-
out for viral entry. Viruses expressing MVC-Sens Env 
were fully inhibited by MVC, while incomplete inhibi-
tion of MVC-Res Env was apparent at saturating MVC 
concentrations, with a mean MPI value of 63 ± 12% (see 
Figure 2a for a representative experiment and Figure 3a). 
This value is lower than those of most MVC-resistant 
viruses from subjects failing therapy identified using the 
PhenoSense™ assay (MPI  >  80%). This is indicative of 
MVC-Res Env having a high level of resistance to MVC, 
in agreement with previous observations [17, 33]. We 
found no cross-resistance of the MVC-resistant virus 
to another low molecular weight, allosteric inhibitor of 
CCR5 (TAK 779) using the U87-CD4/CCR5 cells (Fig-
ure 2b). Substituting the V3 loop within MVC-Sens Env 
by that of MVC-Res Env [MVC-Sens(V3R)] conferred 
resistance to 10 μM MVC, while the mutant of MVC-Res 
with the V3 loop of MVC-Sens Env [MVC-Res(V3S)] was 
fully sensitive to the drug (Figure 3a), in agreement with 
previous work [17]. When considered individually, none 
of the two V3 changes present in MVC-Res Env led to 
MVC resistance (Figure 3a). This suggests that the com-
bination of the two changes within V3 is necessary for 
MVC resistance in U87-CD4/CCR5 cells.
In PBMCs, the MPI values revealed that MVC had 
more modest effects on the infectivity of MVC-Res 
and even slightly increased it in some cases (mean 
MPI  =  −10.8  ±  34%), depending upon the individu-
al’s PBMCs used (Figures  2c, 3c). In contrast, MVC-
Sens remained fully sensitive to inhibition by MVC. 
The MVC-resistant virus modestly resisted to TAK 779 
(MPI  =  95%), but similarly to MVC-Sens (Figure  2d). 
The MVC-Sens(V3R) variant resisted to 10  μM MVC 
as efficiently as MVC-Res, as in U87-CD4/CCR5 cells, 
but unexpectedly, the reverse mutant [MVC-Res(V3S)], 
as well as MVC-Res bearing only either of the two V3 
changes, i.e. the P308S mutation [MVC-Res(−A)] or the 
Alanine insertion in the GPG motif [MVC-Res(S/P)], 
also consistently showed slight levels of resistance to the 
drug in PBMCs as indicated by MPI values close to 90% 
(Figure  3c). In the context of the MVC-Sens Env, how-
ever, the individual V3 changes did not confer resistance. 
These results suggested that regions of the MVC-Res Env 
outside the V3 loop cause a low-level of MVC resistance, 
which is further magnified by the two changes within the 
V3 loop. To further confirm this conclusion, we then per-
formed additional experiments on HEK cells expressing 
higher levels of CCR5 (HEK-CD4/CCR5 cells), as com-
pared to U87-CD4/CCR5 cells and PBMCs [14]. Indeed, 
previous results showed enhanced resistance of HIV-1 
to CCR5 allosteric inhibitors upon increasing the CCR5 
expression levels at the cell surface [37–40]. In HEK-
CD4/CCR5 cells, MVC-Res appeared highly resistant to 
Figure 2 Susceptibility of MVC‑Sens and MVC‑Res to inhibition by 
MVC and TAK 779. U87‑CD4/CCR5 cells (a, b) or PBMCs (c, d) were 
inoculated with equal amounts of MVC‑Sens or MVC‑Res (10 ng of 
Gag p24) in the absence or in the presence of increasing concentra‑
tions of MVC (a, c) or TAK 779 (b, d). Data points are expressed as 
percent inhibition of infection relative to control infection measured 
in the absence of MVC (0%) and were fitted to a sigmoidal dose–
response model with a variable slope. Representative experiments 
out of five independent experiments performed in triplicate are 
shown.
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10 μM MVC (MPI = 12.7 ± 12%), whilst MVC-Sens was 
largely inhibited by the inhibitor (MPI  =  81.2  ±  8.7%) 
(Figure 3e). In agreement with what the results in PBMCs 
had suggested, the MVC-Res-derived variants MVC-
Res(V3S), MVC-Res(−A) and MVC-Res(S/P) partly 
resisted inhibition by MVC (26.4%  <  MPI  <  38.3%), in 
contrast to the MVC-Sens(P/S) and MVC-Sens(+A) vari-
ants, which remained as sensitive as MVC-Sens to the 
inhibitor. Overall, these results confirm that MVC-Res, 
but not MVC-Sens, carries sequence motifs out of the V3 
loop that confer basal resistance to MVC.
As mentioned in the introduction, escape viruses to 
CCR5 antagonists can show changes in their replica-
tion capacity. Here, we observed that the replication of 
MVC-Res is increased by ≈2-fold in U87-CD4/CCR5 
and PBMCs, as compared to MVC-Sens (Figure  3b, d), 
and is only faintly diminished in the presence of MVC 
(Figure  4). Results further showed that this phenotype 
was attributable to the Alanine insertion within the V3 
loop of MVC-Res Env. Indeed, inserting Alanine in the 
context of the MVC-Sens Env [MVC-Sens(V3R) and 
MVC-Sens(+A) variants] enhanced replication by up to 
2.5-fold, while removing Alanine in the resistant virus 
[MVC-Res(V3S) and MVC-Res(−A) variants] resulted 
in a 5- to eightfold loss of the extent of replication (Fig-
ure 3b, d). This indicates that changes in MVC-Res Env 
outside the V3 loop has caused a fitness loss, which was 
compensated for by the Alanine insertion. Interestingly, 
these differences in the replication capacities were no 
longer apparent in HEK-CD4/CCR5 cells expressing high 
levels of CCR5 (Figure 3f ). This suggests that the reduced 
replication of viruses lacking Alanine could be rescued 
under conditions where CCR5 expression is high and 
thus that Ala plays a role in allowing viruses to use CCR5 
more efficiently.
The observation that the Ala insertion confers a repli-
cative advantage to MVC-Res was somewhat unexpected, 
given that we found no virus containing this insertion in 
the Los Alamos HIV Sequence Database. We thus sus-
pected that the Ala insertion might have detrimental 
Figure 3 MVC resistance and viral replicative capacity: The effects of amino acid changes in the MVC‑Sens and MVC‑Res V3 loops and dependence 
on the cell type. U87‑CD4/CCR5 cells (a, b), PBMCs (c, d) or CD4‑ and CCR5‑expressing HEK 293T cells (e, f) were infected with equal amounts (10 ng 
of Gag p24) of MVC‑Sens, MVC‑Res or their related variants S(V3R), R(V3S), S(P/S), S(+A), R(S/P) or R(−A), in the absence or in the presence of 10 μM 
MVC. The percents of infection inhibition (panels a, c, e) were determined as indicated in the legend of Figure 2. Viral infectivities (b, d, f) were 
determined by measuring luciferase activity in the cell lysates 30 h (U87, HEK) or 48 h (PBMCs) post‑infection and are expressed as percent infectiv‑
ity relative to that of MVC‑Sens (100%). Results are mean ± SEM of 3–8 independent experiments performed in triplicate. ***P < 0.001 in unpaired 
two‑tailed Student t test.
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effects on replication in different Env contexts. In line 
with this hypothesis, we found that inserting Alanine in 
the V3 loop of the HIV-1 strains Bx08 and JR-CSF low-
ered replication to almost undetectable levels (Additional 
file 1: Figure S1). This strongly suggests that sequence 
motifs that are common to MVC-Sens and MVC-Res 
Envs, but that are probably absent in most of other Env 
contexts, have permitted the Ala insertion to increase 
viral replication.
In the following sections, we next investigated whether 
resistance of MVC-Res to MVC as well as its increased 
replicative capacity could be related to changes in the 
interactions between gp120 and CD4 or CCR5 and/or in 
env-mediated fusion kinetics.
Binding characteristics of MVC‑Sens and MVC‑Res Envs 
to CD4 and CCR5
The 293-Affinofile cells wherein CD4 and CCR5 expres-
sions can be independently and simultaneously induced 
have widely been used for assessing efficiencies of CD4 
and CCR5 usage (for review see Ref. [34]). Typically, Affi-
nofile cells are infected at varying amounts of CD4 and 
CCR5 and results are mathematically fitted to a 3D-sur-
face function describing the viral isolate’s infectivity fea-
tures. These include the overall entry efficiency or mean 
infectivity M, as well as a sensitivity vector whose direc-
tion (as indicated by the value of the vector angle θ) and 
steepness or amplitude Δ onto the surface plot indicate 
the relative dependence of the virus on CD4 and CCR5 
and the overall rate of responsiveness to changes in CD4 
and CCR5 expression levels, respectively. We found that 
MVC-Sens and MVC-Res had comparable θ values of 
31.9 ± 1.3° and 32.9 ± 1.6°, respectively, indicating that 
both viruses were slightly more responsive to changes 
in CD4 levels than in CCR5 levels (Figure  4). We also 
observed that MVC-Res had increased M and Δ val-
ues reflecting higher infectivity responses, as compared 
to MVC-Sens Env (Figure 4). In the presence of 10 μM 
MVC, MVC-Res showed a significant increase in θ 
(37° ± 1.2°) combined with decreases in the M and Δ val-
ues, indicating that MVC-Res uses the drug-bound form 
of CCR5 less efficiently than the free receptor.
To get further insights into the relative abilities of 
MVC-Sens and MVC-Res Envs to engage CD4 and 
CCR5, we next performed equilibrium binding experi-
ments of monomeric soluble gp120 to CD4- or CCR5-
expressing intact cells or cell membrane preparations. 
In particular, MVC-Sens, MVC-Res, MVC-Sens(V3R) 
and MVC-Res(V3S) gp120 were assayed for their abil-
ity to displace the binding of the anti-CD4 monoclonal 
antibody Q4120 to CD4 stably expressed at the surface 
of HEK 293T cells (HEK-CD4 cells) (Figure 5a). Indeed, 
mAb Q4120 binds to the gp120-binding site on domain 
1 of CD4 [41]. We determined in preliminary satura-
tion binding experiments that mAb Q4120 binds to 
CD4 with a dissociation constant KD of 0.4 ± 0.2 nM, a 
value close to that reported in a recent study [42], and 
then used mAb Q4120 at this concentration in the sub-
sequent competition binding assays. We found that the 
different gp120 variants inhibited mAb Q4120 bind-
ing with the following equilibrium dissociation constant 
(Ki) values: MVC-Sens gp120 (Ki  =  15.5  ±  2.1  nM), 
MVC-Res gp120 (Ki = 43.6 ± 4.1 nM), MVC-Sens(V3R) 
gp120 (Ki =  12.5 ±  2.6  nM) and MVC-Res(V3S) gp120 
Figure 4 Relative efficiencies of CD4 and CCR5 usage by MVC‑Sens and MVC‑Res Envs as assessed by the 293‑Affinofile receptor affinity profiling 
system. 293‑Affinofile cells were induced by minocycline and/or ponasterone A to express 25 different combinations of CD4 and CCR5 expression 
levels and then infected by equal amounts (10 ng of Gag p24) of MVC‑Sens or MVC‑Res in the presence or in the absence of 10 μM MVC. Thirty 
hours post‑infection, luciferase activity was measured in the cell lysates and the three metrics θ (a), M (b) and Δ (c) describing viral infectivity were 
then determined using the VERSA website (http://versa.biomath.ucla.edu). The maximally induced levels of CD4 and CCR5 were 287,000 and 83,000 
receptor/cell. Results represent the mean ± SE of at least four independent determinations. *P < 0.05 in unpaired two‑tailed Student t test.
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(Ki =  41.5 ±  12.5  nM) (Figure  5a). These Ki values are 
within the range of those reported in the literature 
[43, 44]. These results indicate that MVC-Res gp120 
has a threefold lower affinity for CD4 than MVC-Sens 
gp120. They also show that substituting the V3 loop of 
MVC-Sens gp120 by that of MVC-Res gp120, and vice 
versa, do not modify binding affinities to the receptor. 
This is in agreement with previous data showing that 
discontinuous regions of gp120 outside the V3 loop con-
tribute to CD4 binding [45].
To measure the affinity of glycoproteins for CCR5, 
we first performed saturation binding experiments of 
35S-labeled MVC-Sens gp120 or MVC-Res gp120 to mem-
branes from HEK-CCR5 cells in the presence of an excess 
concentration of soluble CD4 (400 nM) (Figure 5b). Spe-
cific binding of 35S-MVC-Sens-gp120 to CCR5 could 
Figure 5 Receptor binding properties of wild‑type and modified gp120 monomers derived from the MVC‑Sens and MVC‑Res viral isolates.  
a Competition of mAb Q4120 binding to CD4‑expressing HEK 293T cells by increasing concentrations of the indicated purified monomeric 
gp120. Results were normalized for nonspecific binding (0%) and specific binding in the absence of glycoprotein (100%, B0) and were fitted to a 
one‑site competitive binding model. A representative experiment performed in duplicate is shown (n = 3). b Equilibrium saturation binding of 
the 35S‑labeled gp120 of MVC‑Sens, MVC‑Sens(P/S) (i.e. MVC‑Sens wherein Pro‑308 is substituted by Ser), MVC‑Res(V3S) (i.e. MVC‑Res whose V3 
loop is replaced by that of MVC‑Sens) or MVC‑Res(−A) (i.e. MVC‑Res lacking the Ala insertion). Curves represent specific binding of glycoproteins 
to crude membranes from CCR5‑expressing HEK 293T cells, determined in the presence of 400 nM sCD4, and obtained by subtracting from total 
binding the non specific binding measured in the presence of 10 μM TAK779 or using parental HEK cells. Data were fitted to a one‑site binding 
model. Representative experiments performed in duplicate are shown (n = 3–4). c Specific binding of 10 nM of the indicated 35S‑labeled gp120 
monomers (+400 nM sCD4) to CCR5‑expressing HEK cells, in the presence (+) or absence (−) of 10 μM MVC, was calculated as in panel (b), and 
then expressed as percent of MVC‑Sens gp120 binding in the absence of MVC (100%). The binding of glycoproteins measured in the presence of 
10 μM TAK779 was considered as nonspecific binding in these experiments. Of note, in some cases, glycoproteins showed levels of binding that 
came slightly lower than this nonspecific binding, explaining why “negative” specific binding are plotted in the panel. Results represent mean ± SD 
of 2–5 independent experiments performed in duplicate. d The panel represents specific binding on CD4‑expressing HEK cell membranes of the 
indicated 35S‑gp120 used at a concentration equal to their Ki value for CD4 deduced from the displacement experiments of mAb Q4120 binding 
shown in panel (a) (see text). One experiment out of two is shown. e Binding of the indicated concentrations of MVC‑Sens (closed symbols and 
straight lines) or MVC‑Res (open symbols and dashed lines) gp120 to 17b (squares and diamonds) or E51 (circles and triangles) mAbs immobilized on 
a CM4 sensorchip, alone (triangles and diamonds) or after preincubation with 200 nM sCD4 (circles and squares). Of note, triangles and diamonds are 
superimposed at the bottom of the panel due to marginal binding in the absence of sCD4. Open and closed squares are also superimposed due to 
similar binding of MVC‑Sens and MVC‑Res gp120s to mAb 17b. f and g Competition of 10 nM 35S‑gp120Bx08 (f) or 
35S‑gp120Sens (g) binding to CCR5‑
expressing membranes by increasing concentrations of the indicated unlabeled gp120 was carried out in the presence of an excess concentration 
of sCD4 (1,000 nM). Results were normalized for nonspecific binding determined in the presence of 10 μM TAK779 (0%) and specific binding in the 
absence of competitor (100%, B0) and were fitted to a one‑site competitive binding model. Representative experiments out of 2–3 independent 
experiments run in duplicate are shown.
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be described as a hyperbolic function, from which we 
deduced a KD value of 7.2 ± 1.1 nM, which is within the 
range of affinity constants reported for other R5 gp120 
[46–48], and a maximum number of binding sites (Bmax) 
of 0.3 ±  0.08  pmol/mg of protein. Unexpectedly, similar 
experiments carried out with MVC-Res gp120 yielded lev-
els of binding that was indistinguishable from nonspecific 
binding determined in the presence of 10 μM TAK779 or 
using membranes from parental HEK 293T cells, regard-
less of the presence or absence of MVC (Figure 5c). Identi-
cal results were obtained when binding was measured on 
intact HEK-CCR5 cells. Subsequent experiments showed 
that insertion of Alanine into the V3 loop of MVC-Res 
gp120 was accountable for its impaired ability to bind to 
CCR5 (Figure  5c). Indeed, introducing Alanine within 
the V3 loop of MVC-Sens gp120 [MVC-Sens(+A)], as 
well as replacing the V3 loop within MVC-Sens gp120 by 
that of MVC-Res [MVC-Sens(V3R)], diminished binding 
to CCR5 to a level similar to that observed for MVC-Res 
gp120, while removing this Alanine residue in MVC-Res 
gp120 [MVC-Res(−A)], or replacing the V3 loop of MVC-
Res gp120 by that of MVC-Sens [MVC-Res(V3S)], fully 
restored binding to the coreceptor (Figure  5c). Of note, 
in contrast to binding to CCR5, we controlled that the 
35S-labeled glycoproteins MVC-Sens, MVC-Res, MVC-
Sens(V3R) and MVC-Res(V3S) bind to similar extents to 
CD4 (Figure 5d). This was confirmed by additional binding 
experiments to CD4 in which the 35S-gp120 were used at a 
concentration equal to their Ki value determined from the 
experiments presented in Figure  5a, i.e. a concentration 
that is expected to bind half the CD4 molecules. As shown 
in Figure 5d, comparable levels of binding were found for 
the glycoproteins under these conditions.
Saturation experiments of gp120 binding also showed 
that the nature of the amino acid at the V3 position 308 
influences the Bmax value, that is the maximum number 
of receptors to which the gp120 can bind. In particular, 
higher Bmax values were measured for MVC-Sens(P/S) 
and MVC-Res(−A) gp120 (Bmax  =  0.53  ±  0.2 and 
0.79 ± 0.14 pmol/mg, respectively) containing a Ser resi-
due instead of Pro, as compared to MVC-Sens and MVC-
Res(V3S) (Bmax  =  0.3  ±  0.08 and 0.36  ±  0.1  pmol/mg, 
respectively) (Figures 5b, c). This finding is reminiscent of 
previous results showing that different mAbs to distinct 
CCR5 epitopes bind to different proportions of CCR5 
molecules at the cell surface [8, 49, 50]. Those results were 
interpreted in terms of CCR5 existing in different confor-
mations/forms, which are differentially recognized by the 
mAbs. Similarly, it could be that the nature of the amino 
acid at position 308 influences the epitopes of CCR5, and, 
in turn, the coreceptor population, to which gp120 binds.
One explanation of why we were unable to detect binding 
of 35S-MVC-Res gp120 to CCR5 might be that the protein 
does not properly fold and/or expose the bridging sheet 
upon binding CD4. To investigate this possibility, we per-
formed surface plasmon resonance experiments to measure 
the binding of MVC-Sens and MVC-Res gp120s to mAbs 
17b and E51. These mAbs belongs to a group of monoclo-
nal antibodies known as “anti-CD4i” which bind to con-
served elements of gp120 induced by CD4 and overlapping 
the bridging sheet and the base of V3 making interactions 
with the CCR5 N-terminus [4, 51]. In the absence of sCD4, 
MVC-Sens and MVC-Res gp120s showed negligible bind-
ing to mAbs (Figure  5e). In contrast, after preincubation 
of gp120s with sCD4, binding to mAbs was dramatically 
induced, indicating that sCD4 has triggered conformational 
changes in both MVC-Sens and MVC-Res gp120s leading to 
the formation of the bridging sheet. Both gp120s exhibited 
similar levels of binding, suggesting that they have compa-
rable affinities for the mAbs and that they have undergone 
similar CD4-induced conformational changes.
Despite that, the apparent lack of binding of 35S-MVC-
Res gp120 to CCR5 made it possible that the glycoprotein 
has an overall decreased affinity for the coreceptor, pre-
sumably as a result of impaired V3 loop/CCR5 ECL2 inter-
actions. To investigate this issue, we next tested the ability 
of unlabeled gp120 to compete for binding to CCR5 with 
either 35S-MVC-Sens-gp120 or 35S-gp120 from the R5 
HIV-1 primary strain Bx08, which show comparable affin-
ity for CCR5 (Ref. [14] and Figure 5f). From displacement 
of 35S-gp120Bx08 binding by unlabeled MVC-Sens gp120 
(Figure 5f), we calculated a Ki value of 4.5 ±  0.2 nM for 
the MVC-sensitive Env, which is similar to the KD value 
determined using the saturation binding experiments 
shown in Figure 5b. A Ki value of 6.3 ± 0.9 nM was simi-
larly calculated for unlabeled gp120Bx08. In striking con-
trast, MVC-Res gp120 only partly displaced 35S-gp120Bx08 
binding in the range of the concentrations used, with an 
estimated Ki value ten-fold higher than that of MVC-Sens 
(Ki  =  50.1  ±  3  nM), consistent with MVC-Res gp120 
having a reduced affinity for CCR5. Similar results were 
obtained using 35S-MVC-Sens gp120 as a tracer (Fig-
ure 5g). Similarly to MVC-Res gp120, the MVC-Sens(V3R) 
variant gp120 showed weak ability to compete with 
35S-MVC-Sens gp120 for binding to CCR5 (Figure  5g). 
On the contrary, removing Ala from the V3 loop of MVC-
Res gp120 (Figure 5f), as well as substituting the V3 loop 
within MVC-Res gp120 by that of MVC-Sens gp120 (Fig-
ure  5g), resulted in an ability of gp120 to displace 35S-
gp120 binding similar to that of MVC-Sens gp120.
Considered altogether, these results indicate that the 
MVC resistance-associated changes in the MVC-Res Env 
sequence, while increasing replication, impair the inter-
actions with CD4 and CCR5, which could not be antici-
pated when using the 293-Affinofile receptor affinity 
profiling system.
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MVC‑Sens and MVC‑Res have different abilities to fuse 
with CD4+ T cells
We next investigated whether the different levels of rep-
lication between MVC-Sens, MVC-Res and their derived 
mutants are due to different entry efficiencies and/or 
kinetic rates. At this stage of the study, we also intended to 
assess whether the receptor binding properties of mono-
meric gp120 recapitulate those of the trimeric Env com-
plex on the virus surface. Indeed, several previous works 
have suggested that the trimeric arrangement of Env may 
alter its binding to HIV entry receptors. For instance, 
recent studies have described that interactions between 
variable loops of adjacent gp120 subunits as well as gp120/
gp41 interactions in the Env trimer are likely to modulate 
the degree of accessibility of the CD4-binding site [52–54]. 
It has also been reported that gp41 can regulate the resist-
ance of HIV to low molecular weight CCR5 antagonists 
[25], presumably as a result of altered CCR5 usage.
To measure the ability of viruses to engage recep-
tors and to enter into cells, we developed a virion-
based fusion assay whose features have previously been 
described [55]. In this assay, we incorporated β-lactamase 
(BlaM)-vpr chimeric proteins into NL4-3Ren-derived 
viral clones expressing either of the MVC-Sens or MVC-
Res gp160 variants (wt or mutants) and then measured 
the transfer of these chimeric proteins into the cyto-
plasm of activated CD4+ T-lymphocytes as a result of 
virus fusion. This transfer was detected by the enzymatic 
cleavage of the BlaM substrate CCF2-AM loaded in the 
target cells, resulting in the change of the CCF2 fluores-
cence emission spectrum from green (520  nm) to blue 
(447 nm). The number of CD4+ T-lymphocytes display-
ing cleaved CCF2 fluorescence was then quantified by 
flow cytometry (Additional file 2: Figure S2).
Equal amounts (30–50 ng of Gag p24) of MVC-Sens and 
MVC-Res were first forced to attach to CD4+ T-lympho-
cytes by spinoculation for 60 min at 4°C, then cells were 
washed twice with culture medium and incubated at 37°C 
for different periods of time (Figure 6a, c). The extents of 
fusion (i.e. the amounts of cells expressing cleaved CCF2) 
increased over time and then reached a plateau value at 
180–240 min that was ≈1.5-fold higher for MVC-Res than 
for MVC-Sens, consistent with MVC-Res fusing more effi-
ciently with CD4+ T cells than MVC-Sens. The addition 
of 10 μM MVC decreased the maximal fusion of MVC-
Res to a level that was not significantly different from that 
of MVC-Sens (Figure  6a, b; Additional file 2: Figure S2). 
In the same way as for viral replication (Figure 3b, d), we 
found that the V3 loop of MVC-Res, and more especially 
the insertion of Alanine, contributes to increasing the final 
extent of fusion (Figure  6b). Indeed, the MVC-Res(V3S) 
and MVC-Res(−A) variants lacking Alanine fused ≈2- to 
3-fold less efficiently than MVC-Res. In contrast, inserting 
Alanine (MVC-Sens(+A)] or the entire MVC-Res V3 loop 
[MVC-Sens(V3R)] into the MVC-Sens sequence increased 
fusion to levels equal or even higher than that of MVC-
Res. Overall, these results strongly suggest that the Ala-
dependent increased replication of MVC-Res relates to 
its enhanced entry efficiency, which is counterbalanced to 
some extent in the presence of MVC.
After normalizing the kinetics to the final extents of 
fusion, it was apparent that the fusion of MVC-Res occurs 
at a slower rate at the early time points (up to 60 min), as 
compared to MVC-Sens, while both viruses fused at the 
same rate afterwards (Figure  6c). Of note, adding MVC, 
although decreasing the final extent of fusion of MVC-Res 
(Figure 6a), did not modify its rate of fusion, in particular 
at the early time points (Figure 6c). Previous experiments 
showed that viral fusion to target cells most often occur 
after a lag time, which represents the time needed for the 
virus to engage CD4 and CCR5, and in doing so to form 
what is named the ternary complex [10, 56]. The delayed 
fusion of MVC-Res might thus be related to the fact that 
the virus takes a longer time to engage CD4 and CCR5, 
compared to MVC-Sens, consistent with the lower affin-
ity of MVC-Res gp120 for both receptors (Figure 5). Alter-
natively, other stages in the fusion of MVC-Res occurring 
after receptor binding might be slowed down. To discrimi-
nate between these two possibilities, we developed time-
of-inhibitor-addition experiments, in which the extents 
of fusion of MVC-Sens or MVC-Res w/or w/o MVC were 
measured at 240  min under conditions where saturat-
ing concentrations of the anti-CD4 and anti-CCR5 mAbs 
Q4120 or 2D7 (50 and 20 μg/ml, respectively) were added 
at different times after the temperature rise to 37°C. Of 
note, these mAbs inhibit HIV attachment to target cells. 
The binding of 2D7 occurs at the N-terminal part of CCR5 
ECL2, to which gp120 also binds, and is unaffected by 
MVC [14, 18]. Thus, we reasoned that if MVC-Sens and 
MVC-Res engage both receptors with similar kinetic rates, 
then they should be equally sensitive to inhibition by the 
mAbs. Alternatively, a greater sensitivity of either of the 
two viruses to mAbs would indicate that it engages recep-
tors with a slower kinetics. In the representative experi-
ments shown in Figure  6d, e, MVC-Res appeared to be 
more efficiently inhibited by both mAbs than MVC-Sens, 
especially at the early time points of fusion, indicating that 
the MVC-resistant virus has delayed kinetics of binding to 
CD4 and CCR5. This is consistent with our results in Fig-
ure 5 showing that MVC-Res gp120 has a lower affinity for 
both receptors, as compared to MVC-Sens gp120. In other 
words, these results strongly suggest that MVC-Res gp120 
both in its monomeric form and as part of the trimeric Env 
complex on the virus surface is defective in its ability to 
bind to CD4 and CCR5. Interestingly, MVC did not affect 
the sensitivity of MVC-Res to 2D7 (Figure 6e), suggesting 
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that MVC does not significantly modify the virus affin-
ity for CCR5, and thus probably its capacity to interact 
with the CCR5 ECL2. Of note, the curves from the fusion 
kinetics (Figure  6c) and those derived from the time-of-
inhibitor-addition experiments had similar overall shapes 
(Figure  6d, e), suggesting that the slower engagement of 
receptors mainly accounts for the delayed fusion of MVC-
Res, while the other steps occurring after binding to CCR5 
likely contributing little to this kinetic lag.
3‑D modeling of the MVC‑Sens and MVC‑Res V3 loop 
structures and dynamics
To better understand how the V3 loop changes in MVC-
Res influence binding to CCR5 and resistance to MVC, 
we first ran molecular dynamics simulations of V3 loops 
from the MVC-Sens or MVC-Res isolates in explicit 
water. Our initial structures were modeled from the 
crystal coordinates of V3 in the context of the HIV-1 
gp120 core complexed to CD4 and to the X5 antibody [3]. 
Five independent simulations of 100 ns each revealed that 
all the residues in the loops experience significant con-
formational fluctuations over time, even in the tip region 
(see supplemental text in Additional file 3 and Additional 
file 4: Figure S3 for details). The tip of the MVC-Res V3 
loop appeared however slightly less flexible than that of 
MVC-Sens (Figures b and c in Additional file 4: Figure 
S3). Previous structural studies using NMR or X-ray crys-
tallography techniques showed that the tip of V3 adopts a 
β-hairpin-like structure, with the GPG motif constituting 
the turn between the two anti-parallel strands [3, 9, 52]. 
Both MVC-Sens and MVC-Res V3 loops have an over-
all similar configuration, with a turn centered on P311 
and three H-bonds between the upstream peptide (from 
P/S308 to G310) and the downstream peptide (from 
Figure 6 Characteristics of MVC‑Sens and MVC‑Res fusion with CD4+ T cells. a Fusion kinetics of BlaM‑vpr‑containing MVC‑Sens and MVC‑Res 
viruses with activated CD4+ T‑lymphocytes are shown, in the presence or in the absence of 10 μM MVC. After virus spinoculation onto cells at 4°C 
and cell washing, fusions were run for the indicated times at 37°C and cells were then loaded with CCF2/AM. Results are expressed as the percent‑
age of BlaM‑vpr positive cells, i.e. cells displaying cleaved CCF2/AM fluorescence (at 447 nm). Results are mean ± SEM of two independent deter‑
minations out of at least five. b Levels of fusion at 2 h. for the viruses MVC‑Sens, MVC‑Res and their related variants Sens(+A), Sens(V3R), Res(−A) 
and Res(V3S), in the absence or in the presence of 10 μM MVC. Results, expressed as fold changes compared to the extent of fusion of MVC‑Sens, 
represent mean ± SEM of 2–10 independent determinations. c The panel represents data from the fusion kinetics of MVC‑Sens and MVC‑Res w/or 
w/o 10 μM MVC that were normalized to the maximal extent of fusion at 300 min. d and e Time‑of‑inhibitor‑addition experiments revealing that 
MVC‑Res interacts with CD4 and CCR5 receptors more slowly than MVC‑Sens. Fusion of viruses with CD4+ T cells was measured at 240 min under 
conditions where 50 μg/ml of the anti‑CD4 mAb Q4120 (d) or 20 μg/ml of the anti‑CCR5 mAb 2D7 (e) was added at the indicated time points after 
cell transfer to 37°C (time zero), in the presence or in the absence of 10 μM MVC. Results are expressed as the percentage of fusion relative to fusion 
in the absence of inhibitor (time 240 min). Representative experiments out of three independent experiments are shown.
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R313 to F315) in the tip (Figure 7). The presence of Ala 
in MVC-Res, however, induces the formation of a bulge 
in the turn, which alters the local conformation of the 
tip. This is notably manifested by an additional H-bond 
between G310 and G312 that was present in 62% of the 
structures simulated for the MVC-Res V3 loop (vs only 
5% in MVC-Sens).
Docking of the MVC‑Sens and MVC‑Res V3 loops into CCR5
We next constructed models of complexes formed 
between CCR5 and either of the two V3 loops (Fig-
ure  8). Docking of MVC-Res V3 was realized onto the 
MVC-bound CCR5 X-ray structure recently released 
[15] (Figure  8b). MVC-Sens V3 was docked onto the 
same CCR5 structure, however after removing the 
inhibitor (Figure  8a). The placement of V3 loops was 
guided by restraints derived from experimental data (in 
particular, we learned from the comprehensive collec-
tion of experimental data presented in Ref. [57]), and 
performed in such a way allowing the tip and the base 
of V3 to interact with ECL2 and the N-terminus domain 
of the receptor, respectively. Similarly to what we previ-
ously reported for Bx08 gp120 [13, 58], we found here 
that MVC-Sens V3 binds to an outer region of CCR5 
that is distinct from the deeply buried binding site for 
MVC. In such a configuration, R313 in the tip of MVC-
Sens (Figure  8a) and Bx08 establishes an ionic bond 
with E283 in CCR5 (Figure  8c), providing a structural 
explanation for the involvement of this acidic residue 
in high-affinity binding of the viral envelope glycopro-
tein [13]. Of interest, E283 is the only residue in CCR5 
that is mandatory for MVC binding [13], making it pos-
sible that a competition takes place between MVC and 
gp120 for strong interaction with E283. Focusing on 
intermolecular interactions, the modeling of the MVC-
Sens V3-CCR5 complex also predicted that a series of 
hydrogen bonds and aromatic interactions tightly pair 
the G310-F315 sequence in V3 and the G178-F182 
sequence in the receptor ECL2 (Figure  8c). Although 
MVC-Sens and MVC-Res V3 loops roughly span the 
same domains of CCR5, MVC-Res V3 showed a differ-
ent mode of CCR5 recognition (Figure  8b, d). Overall, 
it appeared that MVC-Res V3 stands slightly above than 
MVC-Sens V3 in CCR5. Also, MVC-Res V3 established 
a smaller amount of interactions with ECL2 as com-
pared to MVC-Sens, hence providing a molecular basis 
for the decreased affinity of MVC-Res gp120 for CCR5. 
Interestingly, binding of the MVC-Res V3 tip to MVC-
bound CCR5 was independent from ionic bonding to 
E283. The positive charge of R313 could nevertheless 
engage an ionic bond with D276, which is located in 
an upper part of the transmembrane cavity. Of note, an 
ionic bond between D276 and R313 was also observed 
during one-third of the simulation time for the com-
plex between MVC-Sens and CCR5, suggesting that this 
interaction may help position the V3 tip but probably 
plays a minor role in locking it onto CCR5 (Additional 
file 5: Table S1). Modeling of the 3D-complex between 
CCR5 and MVC-Res V3, in the absence of MVC, con-
firmed that the inability to establish an extensive bind-
ing to ECL2 is an inherent property of MVC-Res Env.
Discussion
Understanding how HIV-1 adjusts the use of entry recep-
tors to escape drug inhibition and spread in patients is of 
prime clinical importance. From a therapeutic point of 
6±2%17±22%20±23%
5±4%
20±8%
<1±0.6%11±17%
15±19%8±15%
62±20%
24±9%
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F315A314R313
S308I309G310
F315A314R313
G312
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a b
Figure 7 Organization of the MVC‑Sens and MVC‑Res V3 tips. The frequency of occurrence of hydrogen bonds in the V3 tips of MVC‑Sens (a) and 
MVC‑Res (b) Envs were calculated for every 25 ps segment of each molecular dynamics trajectory. The average rates and standard deviations calcu‑
lated on the five trajectories are indicated near each H‑bond noted with dashed green lines.
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view, such knowledge should prove useful in the devel-
opment of more efficient inhibitors that are less prone 
to generate resistant variants. In this regard, the recent 
development of the 293-Affinofile receptor affinity pro-
filing system has provided valuable information on the 
relative efficiencies of CD4 and CCR5 usage by HIV-1 
variants resistant to CCR5 allosteric inhibitors [16–18, 
32, 39]. In particular, efficient usage of CCR5 by resist-
ant viruses as revealed by low sensitivity vector angles 
θ was shown to be associated with high degrees of 
resistance (low MPI values), leading to the hypothesis 
that the degree of resistance is related to the virus abil-
ity to bind to inhibitor-bound CCR5 [17, 32]. However, 
this hypothesis does not take into account that the virus 
might also take advantage of other CCR5-dependent 
functions to improve viral entry and drug resistance. The 
MVC-resistant HIV-1 clinical isolate MVC-Res we stud-
ied here has similarities with other patient-derived resist-
ant viruses [18, 32], in that it has a high level of resistance 
(Figures 2, 3) associated with high efficiency of free CCR5 
P308I309G310
F315A314R313
G312
P311
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G312
P311
S308I309G310
F315A314R313
F182H181S180
E283
S179
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F182H181S180
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K26
Y316 Y316
c d 
a
Y14
E283
D276
F182S180R
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MVC
F315
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N302
T303
Y14
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b
Figure 8 Molecular models of CCR5 binding the V3 tip of MVC‑Sens Env (left) or the V3 tip of MVC‑Res Env and MVC (right). a and b Three‑
dimensional view of the complexes. The backbone of CCR5 is represented as grey ribbons and the backbone of V3 as green ribbons. The side chains 
of amino acids involved in inter‑molecular interactions are represented as sticks. MVC is represented as sticks. c and d Schematic view of binding 
modes. Light, medium and dark grey boxes represent the receptor residues in ECL2, N‑terminus, and TM7, respectively. H‑bonds are indicated with 
dotted black lines, aromatic stacking with a dotted blue line and ionic bonds with dotted red lines. The thicker the line, the more stable is the interac‑
tion.
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usage in Affinofile cells (Figure 4), in agreement with pre-
vious observations from Gorry’s Laboratory [17]. But 
we showed here that it also displays a slower kinetics 
of CCR5 engagement than its MVC-sensitive counter-
part (Figure  6), probably as a result of a reduced gp120 
affinity for the coreceptor (Figure 5). This indicates that 
parameters other than affinity for CCR5 may contribute 
to the extent to which a virus appears to use CCR5 effi-
ciently in the Affinofile system. Furthermore, the data 
with the Affinofile cells are consistent with MVC-Res 
using MVC-bound CCR5 slightly less efficiently than free 
CCR5 (Figure 4 and Ref. [17]), but this is unlikely related 
to a reduced ability of the virus to bind to MVC-bound 
CCR5, as the inhibitor does not modify the kinetics of 
CCR5 engagement by MVC-Res (Figure 6c, e).
The most striking result in the present study is related 
to the fact that MVC-Res retains high levels of fusion 
and replication that are higher than those of MVC-Sens 
in spite of a dramatically reduced ability to interact with 
CCR5. More generally, correlations exist between viral 
fitness and CCR5 binding affinities [59, 60]. However, 
previous results also showed that anti-CCR5 antibodies 
could strongly inhibit gp120 binding to the coreceptor 
while moderately affecting viral entry [8, 35], indicat-
ing that those processes could require different molec-
ular determinants in CCR5. Our results are actually 
reminiscent of those of a previous work, showing that 
monomeric gp120 derived from clones of a HIV isolate 
resistant to the small-molecule CCR5 inhibitor AD101 
failed to bind to CCR5-expressing cells, in contrast to 
gp120 derived from AD101-sensitive clones [22], sug-
gesting that impairment of CCR5 inhibitor-resistant 
viruses to bind CCR5 is more common than previously 
expected. Previous studies reported that adaptive muta-
tions in HIV-1 Env causing increased affinity for CD4 
[61] or accelerating the fusion process [62] may compen-
sate for impaired interaction with the coreceptor, but we 
showed here that MVC-Res has a three-fold lower affinity 
for CD4 (Figure 5a) and does not fuse more rapidly than 
MVC-Sens (Figure 6).
Where then would the increased replicative capacity 
of MVC-Res have come from? We show here that the 
Ala insertion between G310 and P311 in the V3 loop 
of MVC-Res attenuates the ability of the virus to bind 
to CCR5 and concomitantly increases its fusion (Fig-
ure 6b) and replication (Figures 2, 3) efficiencies. Control 
experiments showed that Ala does not alter the level of 
Env expression on the virus surface (Additional file 6: 
Figure S4). However, this positive effect of Ala on rep-
lication is no longer apparent in cells expressing high 
levels of CCR5 (Figure  3f ), suggesting that Ala plays a 
role in allowing MVC-Res to utilize low levels of CCR5 
for infection. This supports a role for this amino acid in 
allowing MVC-Res to use CCR5 efficiently, in accordance 
with our results using the 293 Affinofile cell system. It 
is increasingly appreciated that CCR5 exists in different 
conformations, which are unevenly distributed at the cell 
surface [46, 49, 50, 63]. In this context, the Ala insertion 
might change the MVC-Res gp120 conformation in such 
a way that the virus interacts preferentially with CCR5 
forms that are colocalized with CD4 and/or are enriched 
in particular membrane domains where the coreceptor 
density is high. This hypothesis is actually in line with 
recent data showing that CCR5 inhibitor-sensitive and 
-resistant viruses recognize distinct conformations of 
the coreceptor [25, 49, 64]. In particular, a virus resistant 
to the small-molecule CCR5 inhibitor vicriviroc (VVC) 
interacting preferentially with CCR5 molecules localized 
in cholesterol-rich membrane domains (lipids rafts) has 
been reported [49]. The privileged recognition by MVC-
Res of membrane regions at the cell surface where the 
CCR5/CD4 ratio is high would explain how the virus 
maintains a high efficiency of CCR5 usage in affinofile 
cells (Figure 4) while having a reduced affinity for CCR5. 
Alternatively, it is known that alterations in the lateral 
distribution of membrane receptors can occur as a con-
sequence of ligand-induced conformational changes [65, 
66]. Similarly, it could be that the binding of MVC-Res 
stabilizes a different CCR5 conformation, as compared 
to MVC-Sens, which might redistribute into discrete 
membrane regions. This particular CCR5 conformation 
could also induce distinct signaling pathways, in particu-
lar those involved in cytoskeleton rearrangements, which 
have been shown to mediate enrichment of receptors at 
the fusion site [67] and to play a role in the formation and 
expansion of the fusion pore [68].
Interestingly, MVC counteracts the positive effect Ala 
has on fusion (Figure  6a) and replication (Figure  4b, c) 
and more generally renders MVC-Res more depend-
ent on higher CCR5 expression levels in 293 Affinofile 
cells without affecting the CCR5 binding affinity. Recent 
computational methods for the prediction of CCR5 con-
formational ensembles showed that MVC stabilizes a 
different set of receptor conformations, as compared to 
free CCR5 [69]. These MVC-bound CCR5 conforma-
tions could differ in their organization at the plasma 
membrane, in their ability to interact with CD4 and/or 
to induce signaling pathways useful for fusion, thereby 
leading to increasing the degree of CCR5 dependence of 
MVC-Res.
Here we identified that two types of sequence motifs in 
MVC-Res gp160 contribute to MVC resistance, although 
it is not clear whether they act in concert or separately. 
Firstly, we found that both the P308S mutation and the 
Ala insertion in the V3 loop of MVC-Res (but not either 
of these changes) are necessary to confer a high level of 
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MVC resistance (Figure  3). Our docking studies pre-
dicted that due to the Ala insertion, the MVC-Res V3 
tip does no longer compete with MVC for interaction 
with E283 in MVC-bound CCR5, in contrast to MVC-
Sens and Bx08 Envs (Figure  8). It is, however, unlikely 
that this process contributes much to MVC resistance, 
because we observed that the presence of Ala alone in 
the context of MVC-Sens or MVC-Res Envs is not suf-
ficient to increase resistance to the inhibitor. Whether 
amino acids outside V3 modulate the extent of MVC 
resistance of MVC-Res, as shown in other Env contexts 
[18, 19], is, however, not known. Secondly, regions out-
side of the V3 loop in MVC-Res Env are sufficient to 
confer partial resistance to MVC on PBMCs (Figure 3c) 
and HEK cells expressing high levels of CCR5 (Figure 3e). 
This was revealed by incomplete inhibition of MVC-
Res-derived mutants of the V3 loop by 10  μM MVC. 
The MVC-Sens isolate also partly resisted inhibition by 
MVC in HEK cells, albeit substantially less efficiently 
than the MVC-Res mutants, but in this case, we believe 
that this is more likely related to increases in the MVC 
IC50 due to high receptor expression levels, as previously 
reported for other MVC-sensitive viruses [14, 40], rather 
than to a genuine basal resistance to the drug. Previous 
work showed that resistance of R5 viruses to MVC in 
MVC-treated patients could occur with no changes in 
the V3 loop [28]. In the case of MVC-Res however, it is 
uncertain whether sequence changes outside V3 confer-
ring MVC resistance arose as a consequence of a MVC 
selection pressure. Indeed, recent data showed that par-
tial resistance to MVC at baseline is a common property 
shared by one-half of clade B and C R5 viruses from the 
chronic stage of infection [38]. In this context, it could 
be that MVC-Res derives from a minor quasispecies 
variant coexisting with MVC-Sens and already resistant 
to MVC before treatment, rather than from MVC-Sens 
itself. This variant could then become dominant thanks 
to the sequence changes in V3 (especially the Ala inser-
tion) during MVC treatment. This hypothesis is actually 
consistent with what has been shown for the CC1/85 
strain, which shows an inherent, low level of resistance 
to CCR5 allosteric inhibitors, which is predisposed to be 
dramatically increased under the selective pressure of 
these inhibitors [40].
Finally, analyzing the phenotypic properties of MVC-
Res in this study pointed to important mechanisms for 
HIV-1 binding to CD4 and CCR5. We observed that 
MVC-Res has a threefold lower affinity for CD4, as 
compared to MVC-Sens, and that this was not related 
to the changes in the V3 loop (Figure  5a). Among the 
sequence elements that could account for this result, 
significant changes in the V1/V2 loops of MVC-Res (see 
Figure 1) are likely to affect the degree of aperture of the 
CD4 binding site [45]. Regarding binding to CCR5, our 
results showing that MVC-Sens and MVC-Res gp120 
have similar affinities for the mAbs 17b and E51, together 
with recent molecular modeling studies [17], suggest 
that the sequence elements of MVC-Res gp120 allow-
ing binding to the CCR5 N-terminus (the bridging sheet 
and the base of V3) are preserved. However, our results 
also strongly suggest that those interactions are not suf-
ficient to maintain a high affinity for CCR5 and support 
a model wherein engagement of HIV gp120 at both the 
CCR5 N-terminus and ECL2 is necessary for conferring 
strong binding to the coreceptor. Indeed, we provide 
here sound evidence that MVC-Res Env has a reduced 
affinity for CCR5, and our molecular dynamics simu-
lations and modeling suggest that this could be due to 
less extensive interactions between the V3 tip and CCR5 
ECL2. Interestingly, loose interaction of MVC-Res gp120 
with CCR5 ECL2 occurred regardless of the presence of 
MVC (Figure 8), thereby reinforcing our conclusion from 
the experimental data that MVC has no influence on the 
already low MVC-Res gp120 affinity for CCR5. One can 
assume however that a link exists between disrupted 
interactions with ECL2 and the occurrence of resistance 
to MVC, as suggested in previous work where deletion of 
V3 has been shown to result in viruses being fully resist-
ant to CCR5 allosteric inhibitors [70–72]. As mentioned 
above, it has been described that one-half of clade B and 
C HIV-1 isolates using CCR5 as a coreceptor exhibits 
intrinsic resistance to MVC, but no clear phenotypic or 
genotypic signatures have been identified [38]. It remains 
an open question if those viruses share the property to 
have succeeded in growing while freeing themselves from 
the obligation to establish strong interactions with ECL2.
Conclusions
Virological failures in patients on MVC therapy are doc-
umented but the knowledge on how R5 HIV-1 strains 
adjust the use of entry receptors to resist MVC and to 
propagate in patients, although of clinical importance, 
is still incomplete. Here, we combined virological and 
pharmacological approaches with molecular dynam-
ics simulations to demonstrate that amino acid changes 
in the viral envelope glycoprotein (Env) associated with 
MVC-resistance can lead to reduced affinities for CD4 
and CCR5 while maintaining high efficiency of viral 
entry and replication. Among the determinants causing 
MVC resistance, we identified in a MVC-resistant virus, 
which had emerged as a dominant viral quasispecies in a 
patient, that a single amino acid insertion in the Env V3 
loop decreases CCR5-binding affinity, but, at the same 
time, augments viral entry. Additional data in cells with 
varying CCR5 levels also suggested that the insertion 
increases the efficiency of CCR5-dependent steps of viral 
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entry other that Env attachment. Overall, these results 
shed light on a new route through which MVC-resistant 
viruses could emerge and grow in treated patients.
Methods
Ethics statement
Blood samples from healthy donors were obtained from 
Etablissement Français du Sang (EFS, the French National 
Blood Agency). Sample use for scientific aim has been 
approved by the French Research Ministry under the 
code: DC-2008-68 Coll 2 “EFS” and by the French Ethi-
cal Committee “CPP Ile de France I” Including College I 
and College II (President Dr Elisabeth Frija) on April 30th 
2009 under the code 08-11887. Consent of donors was 
obtained according to the EFS procedure, which has been 
approved by the competent authorities. All samples were 
coded as required by the French privacy agency (so called 
CNIL, Commission Nationale de l’Informatique et des 
Libertés) (CNIL law: 78-17-January 6th 1978-modified). 
The only biological data available with these samples are 
the results of systematic serological screening tests: anti 
HIV-1 and HIV-2, anti-HCV and HBsAg.
Cell culture and reagents
The procedures for the purification of human peripheral 
blood mononuclear cells (PBMCs) and CD4+ T-lym-
phocytes were previously described [14, 46]. Cells were 
maintained for 2 days in RPMI 1640 medium containing 
IL-2 (300 IU/ml) and phytohemagglutinin (5 μg/ml), and 
then for additional 4–6 days in the presence of IL-2 alone. 
CCR5-expressing HEK 293T cells and the U87-CD4/
CCR5 cell line were previously described [14, 46]. The 
transient expression of CD4 in CCR5-expressing HEK 
293T cells was carried out as described [14]. HEK 293T 
cells stably expressing CD4 (HEK-CD4 cells) were gener-
ated by transduction with the TRIP ΔU3 lentiviral vector 
(a gift from Dr P. Charneau, IP, Paris) encoding the recep-
tor sequence. The 293-Affinofile cell line (a gift from Dr 
B. Lee, Mont Sinai Hospital, New York, NY, USA) was 
maintained in DMEM supplemented with 10% (v/v) foe-
tal bovine serum, 100 μg/ml streptomycin, 100 units/ml 
penicillin, and 50 μg/ml blasticidin (Invitrogen). Recom-
binant soluble human CD4 (sCD4) was produced in the 
S2 cell line and purified on a strep-Tactin column using 
the One-STrEP-tag fused to the CD4 C-tail as a bait (Dr 
S. Pêtres, Plate-forme protéines recombinantes, Institut 
Pasteur). TAK779, MVC and the mAbs 17b and E51 were 
obtained from the AIDS Research and Reference Rea-
gent Program catalog of the National Institutes of Health 
(Bethesda). The anti-CCR5 mAb 2D7 was obtained from 
BD Biosciences. The anti-CD4 mAb Q4120 was provided 
by Dr Q. Sattentau and the NIBSC Centralised Facility for 
AIDS Reagents.
Viral clones
The sequences encoding the MVC-Sens and MVC-Res 
Envs were cloned into the pNL-KspI/Env/NotI-Ren vector 
derived from the HIV-1 proviral clone pNL4-3Ren [36] 
to produce replication-competent viruses expressing the 
Renilla Luciferase reporter gene. The KspI restriction site 
was introduced at the nucleotide position 6214 in pNL4-
3Ren resulting in substitution of Ser for Arg-52 in the vpu 
gene. The Env genes were amplified by PCR using the 
cDNAs provided by Pfizer as templates and the forward 
(5′-TCCCCGCGGCAATGAGAGTGAAGGGGA-3′) and 
reverse (5′-ATAAGAATGCGGCCGCGCCACCCATCT 
TATAGCATAGC-3′) primers and then inserted between 
the KspI and NotI sites into the pNL-KspI/Env/NotI-Ren 
vector. DNA sequences of the cloned full-length Envs 
were confirmed by sequencing. The V3 loop of MVC-
Res Env contains two changes (P308S and G310_P311In-
sAla) compared to MVC-Sens. Mutant clones introducing 
one or both of these V3 loop changes in MVC-Sens or 
reversing them from MVC-Res Env were created by site-
directed mutagenesis. The pBx08Ren and pJRRen plas-
mids, which contain the gp160 from the Bx08 and JR-CSF 
HIV-1 strains, were described previously [14].
Infection inhibition assays
The protocols for the preparation and titration of Renilla 
luciferase reporter viruses have previously been reported 
[14]. Drug susceptibility assays using PBMCs, U87-CD4/
CCR5 and HEK-CD4/CCR5 cells as target cells were car-
ried out as described [14], except that MVC and TAK779 
were added to the cells 2 h prior virus inoculation (10 ng 
p24 Gag/well). Cells were incubated for 30  h (U87 and 
HEK) or 48 h (PBMCs) at 37°C before being lysed. Viral 
replication was then determined by measuring lucif-
erase activity (Renilla Luciferase Assay, Promega, Madi-
son, WI, USA) in the cell lysates using the 96-well plate 
luminometer “Orion” (Berthold). Background activity 
was assessed in the presence of 5 µM Zidovudine (AZT, 
ZDV) and was subtracted from all wells. The percentages 
of inhibition were calculated as [1 −  (luciferase activity 
in the presence of drug/luciferase activity in the absence 
of drug)] × 100. Curve fitting and IC50 calculations were 
performed with the Prism Software using a sigmoidal 
dose–response model with a variable slope.
Affinofile assay
The 293-Affinofile cells were seeded onto 96-well plates at 
a density of 5 × 104 cells/well and then cultured for 24 h 
as described above. Thirty populations of cells expressing 
varying levels of CD4 and CCR5 were then generated by 
inducing cells with two-fold serial dilutions from 0.625 
to 5  ng/ml of minocycline (Sigma) (CD4 induction) and 
from 0.125 to 2 μM of ponasterone A (Invitrogen). Cells 
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were then incubated for 18 h at 37°C, after which receptor 
expression levels and virus infectivities were measured. 
Determining CD4 and CCR5 expression levels at the cell 
surface was performed by incubating cells at 4°C for 1 h 
with saturating concentrations of monoclonal antibodies 
(0.5 or 1 mg/ml) against either CCR5 (clone CTC5, R&D 
systems) or CD4 (clone OKT4, eBioscience) and then with 
a PE-labelled anti-mouse IgG antibody (BD Biosciences, 
ref #550589). Analysis of the PE fluorescence was carried 
out on a CANTO flow cytometer (BD Biosciences). In 
parallel, a conversion ratio between the measured mean 
fluorescence intensities of PE-labelled receptors and the 
amount of CCR5 molecules at the cell surface was deter-
mined by means of saturation experiments of 125I-CCL3 
binding to CCR5-expressing HEK 293T cells, carried out 
as described previously [14]. This method allowed us to 
determine CD4 and CCR5 expression levels at the sur-
face of 293-Affinofile cells that fell well within the range 
of those described in previous works (see the legend of 
Figure 4 and Ref. [34] for comparison). Regarding infec-
tions, the induced 293-Affinofile cells were also incubated 
or not with 10  μM MVC and then inoculated with the 
Renilla luciferase-expressing MVC-Sens or MVC-Res 
viruses (10 ng of Gag p24/well). The luciferase activity was 
determined 30  h post-infection as described above. The 
metrics describing the viral isolates’ infectivity features 
(see text for details) were then mathematically calculated 
using the VERSA computational platform (http://versa.
biomath.ucla.edu), as described previously [34, 73].
Production, 35S‑labeling, and purification of soluble 
monomeric gp120
The gp120 coding sequences from the eight viral clones 
derived from MVC-Sens and MVC-Res Envs were 
amplified by PCR and then inserted into the previously 
described Semliki forest virus-derived expression vec-
tor pSFV2 [14]. Soluble, monomeric gp120 glycopro-
teins were produced and metabolically labeled with 
35S-Cysteine and Methionine as described in Ref. [14]. 
They were then purified by affinity chromatography on 
Strep-Tactin columns (IBA) using the One-STrEP-tag 
fused to the gp120 C-terminus as a bait, and their con-
centrations were determined by Coomassie blue staining 
using BSA as a standard.
Binding assays
Displacement experiments of Q4120 binding to HEK-CD4 
cells by gp120s were performed as follows. Cells (5 × 105) 
in 96-well conical bottom plates were incubated for 2  h 
at room temperature in 0.2 ml of binding buffer (50 mM 
HEPES, pH 7.4, 5  mM MgCl2, 1  mM CaCl2, 1% BSA, 
and 0.1% NaN3) containing 0.4  nM Q4120 and increas-
ing concentrations of unlabeled gp120s. Cells were then 
centrifuged (211×g for 5 min at 4°C), incubated at 4°C for 
1 h with Alexa Fluor 647-conjugated goat anti-mouse IgG 
(dilution 1:500) (Life Technologies) in 0.05 ml PBS supple-
mented with 1% BSA and 0.1% NaN3 and finally washed 
once in the same buffer. Non-specific binding was deter-
mined similarly using control IgG1 (BD Biosciences) as 
tracer or parental HEK 293T cells. Specific Q4120 binding 
to CD4 was then calculated by subtracting non-specific 
binding from total binding of the mAb, as measured by 
flow cytometry analysis (FACSCanto, BD Biosciences). 
The IC50 values for half-maximal inhibition of Q4120 bind-
ing by the gp120s was determined with the Prism Software 
using a one-site competitive binding model. The dissocia-
tion constants Ki for the gp120s were calculated according 
to the Cheng and Prusoff equation Ki = [IC50/(1 + L/KD)] 
[74], where L and KD represent the Q4120 concentration 
and the dissociation constant of the Q4120-CD4 complex 
(KD = 0.4 nM, see text), respectively. The binding experi-
ments of 35S-gp120 to CD4 were performed in eppendorf 
tubes as follows. Crude membranes from HEK-CD4 cells 
(10  μg of proteins), which were prepared as described 
previously [75], were incubated for 2 h at room tempera-
ture in 0.1  ml of binding buffer containing 5% BSA and 
the radiolabeled glycoproteins used at a concentration 
equal to their Ki value for CD4. Non-specific binding was 
determined using the CD4-negative, parental HEK 293T 
cells. Bound and unbound 35S-gp120 were then separated 
by centrifugation (4°C, 5  min, 15,800×g) and removal 
of the supernatant. Membranes were then washed once 
with the washing buffer (50  mM HEPES, pH 7.4, 1  mM 
CaCl2, 5 mM MgCl2, 500 mM NaCl) and resuspended in 
Optiphase Supermix scintillation liquid (PerkinElmer Life 
Sciences). Bound radioactivity was measured in a Wallac 
1450 Microbeta TriLux (PerkinElmer Life Sciences). Satu-
ration binding experiments of 35S-gp120 to CCR5-express-
ing membranes were performed in eppendorf tubes in the 
presence of 400  nM sCD4, as previously described [14]. 
For the displacement experiments of 10  nM 35S-MVC-
Sens gp120 or 35S-gp120Bx08 binding to CCR5-expressing 
membranes by unlabeled gp120s, thirty μg of membrane 
proteins were incubated in eppendorf tubes for 2  h at 
room temperature in 0.1 ml of binding buffer containing 
5% BSA, the radioactive and unlabeled glycoproteins and 
1 μM sCD4. Membranes were subsequently treated as the 
CD4-expressing membranes. Non-specific binding of 35S-
gp120 to CCR5-expressing membranes was determined 
in the presence of 10 μM TAK779. For the analysis of the 
interactions between gp120s and anti CD4i antibodies 
by surface plasmon resonance experiments, N-ethyl-N′-
(diethylaminopropyl)-carbodiimide/N-hydroxy-succimide 
activated CM4 sensorchips were functionalized with 2,300 
or 1,800 RU of mAbs 17b or E51, respectively. Experiments 
were then carried out as described previously [47].
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HIV‑1‑CD4+ T cell fusion assays
The procedure for the production of BlaM-vpr contain-
ing viruses was described previously [76]. CD4+ T cells 
(1  ×  105) were inoculated with the BlaM-Vpr-contain-
ing viruses (50 ng p24 Gag), spinoculated for 1 h at 4°C, 
washed once with culture medium and then incubated 
for different times at 37°C. In time-of-inhibitor-addition 
experiments, fusion was measured at 240 min under con-
ditions where 50 μg/ml of the anti-CD4 mAb Q4120 or 
20 μg/ml of the anti-CCR5 mAb 2D7 was added at the 
indicated time points after cell transfer to 37°C (time 
zero), in the presence or in the absence of 10 μM MVC. 
Cells were then incubated with the CCF2/AM dye (at a 
1.85  μM final concentration) for 2  h at room tempera-
ture in CO2-independent medium supplemented with 
10% FBS. Cells were then washed with CO2-independent 
medium and then fixed in 2% paraformaldehyde. Enzy-
matic cleavage of CCF2/AM by BlaM, which results in 
a change of the CCF2 fluorescence emission spectrum 
from green to blue, was measured by flow cytometry 
(FACSCanto, BD Biosciences).
Molecular dynamics simulations of gp120 V3 loops
Initial structures were modeled from the crystal coordi-
nates of V3 in the context of the HIV-1 gp120 core com-
plexed to CD4 and to the X5 antibody [3]. The residues 
of the gp120 V3 loop ranging from C296 to C331 were 
extracted from the PDB file 2B4C and edited using Sybyl-
X 2.1.1 (Tripos Software Inc, El Cerrito, CA, USA). The 
alanine insertion in the 24-Res model was obtained by 
replacing the GPG segment with the GAPG segment 
using the protein loop search option of Sybyl. Using tleap 
in AMBER 12 (University of California, San Francisco, 
CA, USA), each loop was embedded in an octahedral 
box containing 5,150 water molecules and three Cl− ions. 
The energy of the input system was minimized through 
5,000 steps of steepest descent followed by 5,000 steps 
of conjugate gradient. The system was then equilibrated 
in a two-step protocol including harmonic constraints 
on backbone atoms. In the first step, the system was 
heated from 100 to 300 K using the Langevin dynamics 
algorithm during 20 ps. In the next step, harmonic con-
straints on backbone atoms were decreased from 1 to 
0  kcal/mol.Å2 during 300  ps. Each equilibrated system 
was subjected to constant temperature (300 K) and pres-
sure (1 atm) production run of molecular dynamics (MD) 
simulations. Five dynamics of 100  ns each were carried 
out for the MVC-Sens and the MVC-Res V3 loops. Each 
production run had a random initial velocity assignment. 
All MD simulations were performed using AMBER 12 
with the leaprc.ff03.r1 force field [77]. The ptraj software 
from AmberTools package was used to analyze the MD 
trajectories.
Docking of the gp120 V3 loops into CCR5
The crystal structure of CCR5 was prepared from the 
4MBS PDB file [15]. The rubredoxin fusion protein 
used for crystallization was replaced by the third intra-
cellular loop of the receptor. The missing N-terminus 
was added based on the NMR structure of the peptide 
S7-Y15 determined in complex with gp120 (PDB code 
2RLL, [9]). Sulfate groups replaced the hydroxyl groups 
of Y10 and Y14. The V3 loop was manually docked into 
CCR5 under constraints as follows: (1) the C-terminus 
including the tip (residues 308–330) was modeled from 
the crystal coordinates of V3 in the context of the HIV-1 
gp120 core complexed to CD4 and to the X5 antibody 
(PDB code 2B4C) [3] and positioned into CCR5 so as 
to reproduce the H-bonds established between CXCR4 
ECL2 and the peptide CVX15 (PDB code 3OE0, [78]) 
and to bring the V3 R313 side chain close to the CCR5 
E283 carboxylate; (2) the V3 N-terminus (residues 296–
307) was modeled from the crystal coordinates of V3 in 
the context of the HIV-1 gp120 core complexed to CD4 
and to the 412d antibody containing two sulfotyrosines 
(PDB code 2QAD, [9]) and positioned into CCR5 so 
as to bring the side chains of N302 and T303 close to 
CCR5 Y14. Modifications in V3 to match to MVC-Sens 
and MVC-Res sequences were performed as described 
above. Molecules were handled and edited using MOE 
2013 (Chemical Computing Group, Montreal, QC, Can-
ada). The complex was then placed into a hydrated lipid 
bilayer and relaxed using MD with AMBER 14 (Univer-
sity of California, San Francisco, CA, USA). In detail, 
84 palmitoyloleoylphosphatidylcholine (POPC), 84 pal-
mitoyloleoylphosphatidylethanolamine (POPE) and 42 
cholesterols composed the bilayer that was surrounded 
by 15,877 water molecules, 55 Cl− ions and 43 K+ ions. 
After energy minimization, the system was heated to 
100 K at constant volume during 500 ps, while fixing the 
positions of all atoms except in water using harmonic 
constraints of 10 kcal/mol.Å2. In a second stage of 500 ps 
heating, the temperature was raised to 300 K at constant 
pressure, keeping only the CCR5 and V3 atoms rigid. The 
equilibrated system was then subjected to constant tem-
perature (300 K) and pressure (1 atm) simulations. Dis-
tance and angular restraints between V3 and CCR5 and 
constraints on receptor atom positions were imposed 
during the simulation according to the schemes given in 
Additional files 7: Figure S5 and 8: Figure S6. The rep-
resentative structures of the complexes were obtained 
by clustering the last 120 frames corresponding to 60 ns 
simulation without constraints or restraints between the 
V3 tip and CCR5. Intermolecular interactions between 
the V3 tip and CCR5 ECL2 monitored during the last 
60  ns of simulation were reported in Additional file 5: 
Table S1.
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Additional files
Additional file 1: Figure S1. Insertion of Ala in the GPG crown impairs 
the replicative capacity of the HIV‑1 strains Bx08 and JR‑CSF. U87‑CD4/
CCR5 cells were infected by 10 ng Gag p24 of the indicated viral isolates 
and luciferase activity in the cell lysates was measured 24 h post‑infection. 
Results are expressed as percent replication of the Ala‑containing viruses 
relative to that of their wild‑type counterparts (100%). The RLU levels for 
Bx08 and JR‑CSF were ≈ 900000 and 700000, respectively. A representa‑
tive experiment out of three independent experiments performed in 
triplicate is shown.
Additional file 2: Figure S2. Effects of MVC on fusion of MVC‑Sens or 
MVC‑Res to CD4+ T‑lymphocytes. BlaM‑Vpr‑containing viruses (50 ng p24 
Gag) were incubated for 3 h. at 37°C with 1x105 CCF2‑loaded, activated 
CD4+ T‑lymphocytes in the presence or in the absence of 10 μM MVC. 
Viral fusion was evaluated by measuring the enzymatic cleavage of CCF2 
by flow cytometry. The panels indicate the percentages of cells positive 
for cleaved CCF2. A representative experiment is shown.
Additional file 3: Supplemental text (related to Figure 7 and additional 
file 4).
Additional file 4: Figure S3. Structure and dynamics of free V3 from 
the MVC‑Sens (grey) or MVC‑Res (black) isolates. (A) Time series of root 
mean square deviation (RMSD) values for all atoms of the V3 loops, using 
as reference the average coordinates computed from the five independ‑
ent simulations. (B) The phi and psi angular fluctuations were calculated 
and averaged by residue for every 25 ps segment of the five molecular 
dynamics trajectories. Standard deviations are reported for phi (top) and 
psi (bottom) backbone torsion angles. (C) The average RMS fluctuations 
(RMSF) were calculated for the carbon alpha atoms of the V3 loop residues 
from the ensemble of structures after superimposition of residues 296 to 
330 (complete V3 loop, plain lines) or superimposition of residues 308 to 
315 (V3 tip, dotted lines).
Additional file 5: Table S1. Intermolecular interactions between the V3 
tips and CCR5.
Additional file 6: Figure S4. Western blot analysis of gp120 and Gag 
p24 expression on MVC‑Sens, MVC‑Res, MVC‑Sens(V3R) and MVC‑Res(V3S) 
viral particles. Three hundred ng Gag p24 of the different viral isolates 
were solubilized in lysis buffer (100 mM (NH4)2SO4, 20 mM Tris‑HCl (pH 
7.5), 10 % glycerol, and 1% Triton X‑100) and then loaded onto Biorad Cri‑
terionTM XT 4‑12% Bis‑Tris Gels under reducing conditions. Virus‑associated 
gp120 and p24 were visualized using a sheep anti‑HIV‑1 gp120 polyclonal 
antibody (AALTO Bio Reagents LTD.) and a mouse anti‑HIV‑1 p24 
monoclonal antibody (clone 183‑H12‑5C) (NIH AIDS Reagent Program), 
respectively, and then with the appropriate HRP‑conjugated secondary 
antibodies (VECTOR). Bands were developed by enhanced chemilumi‑
nescence (Thermo Scientific) and were quantified using a LAS‑1000 CCD 
camera (Image Gauge Software, Fuji Film Co., Tokyo, Japan). The figure 
shows that the viral isolates have gp120/p24 ratios R that are in the same 
range (R = 1, 1.15, 1.24 and 0.81 for MVC‑Sens, MVC‑Res, MVC‑Sens(V3R) 
and MVC‑Res(V3S), respectively). A representative experiment out of two 
is shown.
Additional file 7: Figure S5. Molecular modeling of the complex 
between CCR5 and MVC‑Sens V3. The graphic shows time series of RMSD 
values of the complex using as reference the input coordinates. The table 
indicates which constraints or restraints were imposed on the system dur‑
ing the simulation. bb : backbone atoms, all : all atoms, sc : side chains.
Additional file 8: Figure S6. Molecular modeling of the complex 
between MVC‑bound CCR5 and MVC‑Res V3. The graphic shows time 
series of RMSD values of the complex using as reference the input coor‑
dinates. The table indicates which constraints or restraints were imposed 
on the system during the simulation. bb : backbone atoms, all : all atoms, 
sc : side chains.
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